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Abstract 
 
In the present study, the origin of the anti-quorum sensing (QS) activities of several members of a 
recently synthesized and in vitro tested class of lactone and thiolactone based inhibitors were 
computationally investigated. Docking and molecular dynamic (MD) simulations and binding free 
energy calculations were carried out to reveal the exact binding and inhibitory profiles of these 
compounds. The higher in vitro activity of the lactone series relative to their thiolactone isosteres was 
verified based on estimating the binding energies, the docking scores and monitoring the stability of the 
complexes produced in the MD simulations. The strong electrostatic contribution to the binding 
energies may be responsible for the higher inhibitory activity of the lactone with respect to the 
thiolactone series. The results of this study help to understand the anti-QS properties of lactone-based 
inhibitors and provide important information that may assist in the synthesis of novel QS inhibitors.  
 
Keywords: Quorum Sensing; lactone inhibitors; Docking; Molecular dynamics; AMBER. 
*
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1. Introduction 
 
Treatment of bacterial infections is a major global challenge. Bacteria continue to develop resistance to 
current anti-bacterial agents and the problem is becoming more wide-spread [1-4]. It is estimated that 
bacterial resistance can increase mortality and morbidity by a factor of two [5]. The problem is even 
worse in developing countries where appropriate medical services cannot always be effectively 
delivered [6]. An attractive pathway to resolve the problem of resistance is targeting bacterial quorum 
sensing [7-11].  
 
Quorum sensing (QS) is a communication mechanism by which bacterial cells organize biological 
processes that are not possible with a single bacterium, such as toxin production and biofilm formation 
[8,12,13]. This mechanism includes binding of specific signal “hormone-like” molecules called “auto-
inducers” to specific intracellular or membrane bound receptors [8,12,14]. This binding triggers a wide 
range of intracellular reaction cascades in Gram positive and Gram negative bacteria to carry out the 
required biological process [15,14]. A typical QS system is composed of three components, (i) A 
bacterial synthase (e.g. LuxI) that synthesizes the “auto-inducer”, (ii) The auto-inducer which is 
typically an acylhomoserine lactone (AHL) derivative and (iii) A transcription regulatory protein, such 
as LuxR or its homologues. LuxR protein binds to DNA and activates gene expression once the level of 
the AHL reaches a critical threshold depending on the bacterial population density [16,17].  
 
Various mechanisms of this AHL induced QS activation have been proposed and three mechanisms are 
the most widely accepted. In the first mechanism, the AHL induced conformational changes on LuxR 
enable LuxR to bind DNA and trigger the transcription process [18,17]. In the second mechanism, the 
AHL induced LuxR conformational changes relieve the repressor effect exerted by LuxR on the target 
genes and enable gene transcription [19,20]. In the third mechanism, extracellular AHL is detected by 
membrane bound receptors that trigger a wide range of intracellular reactions leading to gene 
expression [21,8].  
 
Bacteria cannot easily develop an acquired resistance against QS inhibitors. As a result, QS inhibition 
is seen as an excellent weapon to fight against bacteria [8,16]. A number of distinct methods have been 
described to inhibit QS. In one of such methods, the AHL synthase is inhibited by small molecule 
analogues of organic compounds involved in AHL biosynthesis [22-24]. Enzymatic hydrolysis of the 
AHL molecule by acylases, hydrolases and lactonases has been reported as an excellent defense 
mechanism for other organisms against bacteria [22-24]. The third and most widely investigated 
method is the use of small AHL analogues that competitively inhibit AHL binding to the LuxR proteins 
and their homologues, such as the LasR protein [24,9,7,25-28]. These classes of inhibitors are referred 
to as “AHL antagonists”. In the present study, two in vitro tested lactone and thiolactone series of AHL 
antagonists are computationally investigated to understand the origin of their anti-QS activities.  
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The most commonly investigated AHL antagonists are those belonging to lactone, thiolactone and 
furanone classes of organic compounds [24,9,7,25-29]. This is due to the structural similarities between 
these molecules and the naturally occurring AHL auto-inducers. These auto-inducers can have different 
structures depending on the producing organism. In most cases, the auto-inducer is composed of a five-
membered lactone head and an acyl group spacer connecting this head to a hydrophobic chain tail. The 
length of the tail and its chemical structure differ between AHL derivatives and can affect the potency 
and the intrinsic activity (agonist or antagonist) of a given AHL [27,22,30,8]. This may facilitate the 
tuning of the effect for a given inhibitor or inducer so that it can selectively inhibit or activate a 
particular type of bacterium. Some authors suggested the ability of several molecules to inhibit QS 
although they are not structurally related to AHL [31]. 
 
Unfortunately, computational studies on this important class of inhibitors are rare which may be due to  
the limited availability of crystal structures of the LuxR proteins complexed with their corresponding 
antagonists [28,32-34]. The need for detailed investigation of QS inhibition at the molecular level is 
necessary for the understanding of QS process and the future development of effective drugs. In the 
current study, the binding mode of a recently synthesized and tested thiolactone group of AHL 
antagonists against LuxR proteins [8] was investigated. Docking and molecular dynamics (MD) 
simulations were carried out against a recently resolved X-ray crystal structure of LuxR protein from 
Chromobacterium violaceum (C. violaceeum). The C. violaceum LuxR protein (CviR) was co-
crystallized with an inhibitor from a similar study but having a lactone ring instead of thiolactone, i.e., 
sulphur has been replaced by its isosteric oxygen atom [7]. In addition to the reported thiolactone 
series, the corresponding lactone analogues are computationally investigated to understand the 
differences in binding between the two groups. Also, it has been shown that the thiolactone analogue of 
the co-crystallized inhibitor is 10-fold less effective than the lactone inhibitor, a detailed analysis is 
carried out to understand the basis of this difference. 
 
2. METHODS AND COMPUTATIONAL DETAILS  
 
The chemical structure of the lactone and thiolactone back bone skeleton is given in Figure 1. When 
the X atom in the penton ring is oxygen, i.e. X=O, the structures are lactones, whereas the structures 
become thiolactones if X=S in the same figure. The R-group at the end of the chain in the back bone 
structure is replaced by different sixteen groups as listed in the figure, which in total produced 32 
compounds: 16 thiolactones and 16 lactones. The thiolactone series is denoted as “TL”, the lactone 
series is denoted as “L” as marked in the same figure, in which the original co-crystallized lactone 
inhibitor is denoted as L3 and its thiolactone isostere is denoted as TL3. 
In the protein preparation, the crystal structure of CviR (a LuxR protein) co-crystallized with 
chlorolactone (L3) antagonist was taken from the PDB (PDB entry: 3QP5) [7]. Figure 2 gives a three-
dimensional (3D) representation of the CviR protein monomer. The complex was prepared using the 
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protein preparation wizard in Maestro 9.2 [35]. The crystallized protein structure is a tetramer, one 
chain is kept, and others are deleted in the present study and saturated by hydrogen atoms but the water 
molecules are deleted. Similar to a precious study[36,37], the missing residues were added and refined 
using Prime 3.0 [38]. The N-acetyl (ACE) and N-methyl amide (NMA) groups were added to cap the 
uncapped N and C termini respectively. H-bond network optimization was carried out assuming a 
neutral pH of the solution. The protonation states of titratable amino acids were assigned at the same 
pH. An all atom impref minimization step was carried out to remove unfavorable steric clashes until a 
convergence was reached or with a maximum RMSD of 0.3 Å from the original conformation. No 
steric clashes were reported after the final minimization step. 
 
Once the protein structure is set up, a receptor grid was prepared with the receptor grid generation 
module in Glide 5.8 [39]. The binding site was determined as a box around the ligand that was centered 
inside the box. Four H-bonds constraints with the nearby residues (Tyr80, Trp84 Asp97, and Ser155) 
were set in the grid preparation.  
Ligand molecules were optimized at the RM1 [40] semiempirical level of theory as implemented in the 
Semiempirical module in Maestro 9.2 [35].  Ligand partial atomic electrostatic potential charges (ESP) 
charges were assigned at the HF/cc-pVTZ level of theory using Jaguar [41]. 
Next, docking and scoring of the study employed the flexible ligand docking, which was performed 
through the Glide extra precision mode (Glide XP) [42]. In order to increase the sampling space, a 
maximum of 50.000 initial ligand poses were kept in the initial phase of docking. A scoring window of 
poses within 1000 kcal·mol
-1
 from the best scoring pose were retained, from which a maximum of 800 
poses per ligand were subjected to 200 steps of energy minimization. A potential ligand pose was 
considered only when at least three of the four predetermined H-bond constraints were satisfied. 
Rescoring the docked poses was done using the Prime/MM-GBSA module in Prime 3.0; residues 
within 6Å of the ligand were considered flexible.  
 
Finally, molecular dynamics (MD) simulations were conducted for the co-crystallized lactone 
inhibitors and its thiolactone analogues with both the dimeric and the monomeric forms of the CviR 
protein, i.e. four inhibitor-protein complexes were simulated. That is, the L3/TL3-CviR monomer 
complexes and the L3/TL3-CviR dimer complexes. To remove any potential bias from different 
starting configurations, the TL3 complexes were obtained by mutating the oxygen atom of the 
experimentally resolved L3 complexes to a sulphur atom.   
 
The structure preparation and the following MD simulations were performed using AMBER 12 
software package [43] applying the ff03 force field  [44]. Single point calculations of the 
corresponding inhibitors were performed at the HF/6-31G* using the Gaussian 09 program [45]. The 
inhibitor charges and other parameters were obtained using the RESP fitting  [46] procedures and  the 
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general AMBER force field (GAFF) [47]. The complexes were then solvated in a box of TIP3P [48] 
water with a buffer size of 15Å and were neutralized by counter ions. 
  
Each system was then subjected to four consecutive minimization steps. In each step, water molecules 
and ions were allowed to move freely for a 1000 steps of steepest descent minimization followed by 
4000 steps of conjugate gradient minimization holding protein and inhibitor atoms constrained to their 
original positions by a force constant of 100 kcal·mol
-1
Å
-2
, then gradually releasing the force 
constraints to 50, 5 and zero (no constraints) kcal·mol
-1
Å
-2
, respectively. Following minimization, two 
consecutive steps of heating and equilibration were performed. Each system was gradually heated in 
the NVT ensemble from 0°K to 300°K for 30 ps with a time step of 1 fs, applying a force constant of 
10 kcal·mol
-1
Å
-2
 on the protein and inhibitor coordinates. Langevin dynamics with the collision 
frequency γ of 1 ps-1 for temperature control was employed. A further 1 ns simulation in the NPT 
ensemble was performed to equilibrate the system density by applying a time step of 2 fs, which 
required the use of SHAKE algorithm [49] to constrain all bonds involving hydrogen atoms. The 
temperature was controlled using Langevin dynamics with the collision frequency γ of 1 ps-1 and is 
kept at 300°K. The pressure was kept at 1 bar by applying a Berendsen barostate with a pressure 
relaxation time of 1 ps. Each system was again relaxed in the NVT ensemble for 20 ns followed by 30 
ns production simulation at 300°K using Berendsen temperature control [50]. In all simulation steps, 
long-range electrostatics were computed using the particle mesh Ewald (PME) and a 12 Å real space 
cut-off [51]. The edge effect was removed by applying periodic boundary conditions. For MD 
simulations of the monomeric chains, weak constraining forces were applied on the DNA binding 
domain plus the flexible coil segments of the monomeric chain. All MD simulations were carried out 
using the PMEMD module of AMBER12. For the binding energy evaluation from the trajectory, the 
MM/PBSA module of AMBER12 was used and using every second frame collected from the MD 
simulations, i.e. around 3750 snapshots were used [52]. 
3.  RESULTS AND DISCUSSION  
3.1. Docking and scoring 
To the best of our knowledge, the first available X-ray crystal structure for a member of the LuxR 
family of proteins co-crystallized with a pure antagonist is the CviR protein from Chromobacterium 
violaceum (PDB code: 3QP5) [7]. In that study, CviR was co-crystallized with various ligands of either 
agonistic or antagonistic activities. Agonist binding to CviR results in conformational changes and 
activation of the dimer to bind DNA and trigger DNA transcription. The ligand induced conformational 
changes determine the intrinsic activity of a given ligand to be either an agonist or an antagonist. In 
addition, it has been shown that subtle ligand structural differences can affect the potency and the 
intrinsic activity of a given ligand dramatically [27,22,30,8]. Moreover, the same ligand can work as an 
agonist or an antagonist depending on the protein homologue and the bacterial strain [27,22,30,8]. 
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These unique properties urge further and extensive theoretical and experimental work to shed the light 
on the complex mechanism that controls QS signaling. 
 
Figure 2 presents a solid ribbon representation of a CviR protein monomer. The protein is made of two 
distinct domains, a Ligand Binding Domain (LBD) and a DNA Binding Domain (DBD) and the two 
domains are connected by a short flexible coil. The LBD is the bigger domain and is composed of α-
helices and β-sheets while the DBD is composed of a few α-helices. The exact ligand binding site is 
shown as a solid surface inside the LBD. 
 
AHLs or their analogues are characterized by a unique “sperm-like” structure composed of two parts, 
head and tail. The lactone head is able to form an H-bond with the nearby Trp84 residue, while the acyl 
group forms H-bonds with Asp97, Tyr80 and Ser155. The tail part is buried in a hydrophobic pocket 
made of Val, Leu and Ile residues. Figure 3 shows two 2D ligand interaction diagrams for an agonist 
(PDB code: 3QP1) and an antagonist (PDB code: 3QP5). 
 
Table 1 reports the docking scores for the inhibitors under study using the conventional docking scores 
and the Prime-MM/GBSA scores. Inhibitors are given in the table according to their XP Gscore. From 
the correlation with the available experimental IC50 data, the Prime MMGBSA DG bind vdW score 
achieved the best correlation with experimentally measured IC50 (r(pearson) = 0.52). Glide Emodel 
performed reasonably well (r(pearson) = 0.49).The thiolactone derivatives showed overall lower scores 
than their corresponding lactone analogues, which is consistent with the experimental findings. Only 
the XP Gscore was able to identify the original lactone inhibitor (L3) followed by the TL12 thiolactone 
derivative to be the best inhibitors among the two series. 
 
Figure 4 represents the 2D and 3D interaction diagrams of some selected antagonists with the CviR 
receptor. In general, antagonists binding modes to the receptor are similar to the original co-crystallized 
antagonist. This is a result of the strict docking criteria which are applied for accepting poses. The 
lactone carbonyl forms a direct H-bond with the conserved Trp84 residue, the acyl group –NH forms 
an H-bond with Asp97 and the carbonyl oxygen forms H-bonds with Tyr80 and Ser155. As the 
libraries are focused, subtle ligand differences which are correlated directly with inhibitory activity 
need to be paid greater attention. 
 
The main difference between the two libraries is the isosteric replacement of the “S” atom in the TL 
series by an “O” atom in the L series. The observed activity differences between the two libraries may 
be related to the H-bond strength that may exist between the sulphur or oxygen ring atoms and the 
nearby –C(7)H of Trp84. However, it is known that heterocyclic H-bond acceptors are grouped in the 
“weak H-bond” category of acceptors [53]. Therefore, potential large effects of this H-bond (if any) are 
not expected. The effect of this substitution is discussed in detail in section 3.2. 
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The major difference between any pair of inhibitors within the same library (TL or L) is the chemical 
structure of the hydrophobic tail chain. Studies have indicated that the structure and the length of this 
chain can affect the potency and the intrinsic activity of a given ligand [27,22,30,8]. In the two 
inhibitor libraries, the terminal aromatic group forms a direct, sandwich type π-π stacking interaction 
with Tyr88 aromatic ring. Assuming all inhibitors have a similar binding mode, the overall binding 
strength (within a given library) is directly correlated with the strength of this π-π stacking interaction.  
 
As can be seen in Table 1, substitution with Electron Donating Groups (EDG), such as methoxy 
groups, resulted in a dramatic reduction in the activity regardless of the position of this substitution. 
They also had the overall worst docking scores. For example, the IC50 of –meta (TL10) and –para 
(TL7) substituted methoxy group derivatives are 37 µM and 11 µM, respectively. On the other hand, 
Electron Withdrawing Group (EWG) derivatives, such as halogenated derivatives, have the highest 
inhibitory effect and best docking scores as well. For example, the top scoring inhibitors (according to 
the Glide XP score) were the L3 and the TL12 inhibitors, which have IC50 values of 0.38 µM and 0.63 
µM, respectively. The lactone derivative of TL12, the L12 antagonist, exhibited a higher XP Gscore (-
10.02). This makes the halogenated derivatives, particularly the poly-halogenated ones, better 
candidates for further synthesis and biological testing. 
 
3.2. Molecular dynamic simulations 
 
A difficult challenge in performing a meaningful MD simulation for LuxR proteins (including CviR) is 
their inherent flexibility. This inherent flexibility is obvious knowing that the protein can adopt 
different conformations depending on their activation states as well as the accompanying ligand. This 
flexibility enables different proteins to carry out their functions properly [54]. CviR is a homo-dimer 
composed of two identical and overlapping chains of about 250 amino acids each. Each monomeric 
chain is composed of an LBD connected to a DBD through a highly flexible coil.  
 
An accurate measure to assess the stability of the protein complexes during MD simulations is the root 
mean square deviations (RMSD). Figure 5 (a-b) displays the RMSD plots for the Cα atoms of each 
protein in the production simulation period. As can be seen in the plots, the L3 complexes, in both the 
monomeric and dimeric forms, have higher stabilities than their TL3 counterparts. The average RMSD 
for L3-CviR dimer is ~ 1.6-1.8 Å. For the TL3-CviR dimer complex, the average RMSD value is 
higher with an average value of ~4 Å. This illustrates the enhanced stability of the CviR dimer with L3 
over TL3. Interestingly, the same is true for the monomeric case such that the L3 complex with the 
monomeric CviR is more stable than its TL3 counterpart.  
 
To examine the origin of this reduced stability of the TL3 complexes with respect to the L3 complexes, 
a more detailed analysis on a per-residue basis was conducted using the per-residue heavy atoms 
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RMSFs (root mean square fluctuations). Figure 6(a-b) displays the heavy atoms RMSF plots of the four 
complexes during the simulation time. As can be seen, the L3 complexes show enhanced stability over 
the TL3 complexes. For the CviR dimer complexes, the LBDs of both chains (A and B) possess an 
overall lower RMSF during the simulation period than the DBDs. For the monomeric complexes with 
L3 and TL3, and as a result of the weak constraints applied on the “DBD+coil” segment of the 
monomeric chains, the whole monomer is of a comparable RMSF value. The enhanced flexibility of 
the DBD segment of the dimeric protein is expected given the fact that this segment is responsible for 
binding to DNA upon activation [55]. It would be also interesting to investigate the detailed binding 
event of this segment to DNA upon agonists or antagonists binding. However, such a complex process 
is beyond the capability of conventional MD simulation and other MD paradigms, such as accelerated 
MD, may be more suitable [56]. Research in this direction is currently in progress.    
 
It is important to study the stability of the observed H-bonds as a function of the simulation time. Thus, 
Figure 7 (a-d) displays some selected H-bonds monitored during the simulation time for the four 
complexes. The first and most important H-bond is the one formed with Trp84 residues and it has been 
already identified in the docking section. As can be seen in Figure 7, the average value for this H-bond 
is ~ 1.9-2.3 Å for all complexes. The L3 complexes have less fluctuation during the simulation time 
than their TL3 counterparts. The same is true for the H-bonds formed with the Tyr80 residue in all 
complexes. For the L3 and TL3 complexes with the monomeric CviR chains, higher fluctuations of up 
to 3.5 Å (L3) and 4.3 Å (TL3) were observed. Interestingly, and in most cases, the H-bond which is 
observed via docking between the amide carbonyl and the Ser155 residue is not stable in the MD 
simulation and the adopted rotomer shifts the –OH group to the other side (Figure 8).  
 
3.3. Total and decomposed MM-PB/GBSA binding energies  
 
 
Table 2 reports the binding energy scores for L3 and TL3 inhibitors according to the AMBER-
MMPB/GBSA scores as implemented in AMBER12. The AMBER-MMPB/GBSA binding energy 
scores take the advantage of statistical averaging over many potential conformations that are produced 
from the MD trajectories. In the AMBER-MMPB/GBSA calculations, only the inhibitor-dimer 
complexes are considered. To further enhance statistical precision and knowing that each complex 
contains two inhibitors, each inhibitor is treated separately as a ligand in a separate run. Final data 
reported are the average values of the two independent AMBER-MMPB/GBSA calculations for each 
complex. 
 
As can be seen in Table 2, the major term that favors the binding for both inhibitors is the vdW 
lipophilic term (∆EvdW). Interestingly, although the vast majority of the binding site residues are 
lipophilic residues, the electrostatic (∆Eele) term still exhibits a significant contribution to the binding. 
This large contribution emphasizes the importance of the H-bond interactions which are electrostatic in 
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nature. It would be also interesting to use certain advanced techniques, such as alanine-scanning 
[57,58], to study the effect of mutations in residues responsible for these H-bonding interactions. 
Research in this direction is currently in progress. 
 
For TL3, the ∆EvdW interaction is given by -46.56 kcal·mol
-1
, this value is slightly higher than that for 
L3 which is given by -45.31 kcal·mol
-1
. On the other hand, L3 exhibits a larger contribution from the 
∆Eele term (-33.54 kcal·mol
-1
) than TL3 (-28.37) i.e., ∆∆Eele is equal to 5.17 kcal·mol
-1
 which is almost 
equal to the energy contribution of a full H-bond. This larger contribution of the ∆Eele term for L3 than 
TL3 may be responsible for the fact that L3 is ~10 times more active than TL3 in the in vitro assay 
[8,7]. Regarding total binding energies as expressed by the ∆G values, L3 shows higher binding energy 
according to the AMBER-MM/PBSA score (-63.54 kcal·mol
-1
) than TL3 (-59.11 kcal·mol
-1
). The same 
is true for the AMBER-MM/GBSA score of L3 (-48.65 kcal·mol
-1
) compared to that for TL3 (-47.60 
kcal·mol
-1
). 
 
Decomposition of the binding energy on a per-residue basis is very important to understand the binding 
mode and assess the role of each residue in the binding. Figure 9 displays the per-residue binding 
energy analyses for the two complexes during the simulation period. For the ∆EvdW and the ∆Eele 
interaction terms, only residues showing large contributions are selected. Figure 9a displays the per-
residue contribution for the ∆EvdW interaction term. As can be seen, the major contribution to the ∆Evdw 
term is from the Tyr88 via a strong π-π stacking interactions, consistent with the observations from the 
docking study. The contribution of this residue to the ∆Evdw term for both inhibitors is similar, -2.57 
kcal·mol
-1 
for L3 and -2.59 kcal·mol
-1
 for TL3. This is because the terminal aromatic ring which is 
responsible for the π-π stacking interaction with this residue is identical in both inhibitors (L3 and 
TL3). The second most important ∆EvdW interaction is from the Trp111 residue which contributes more 
to TL3 (-2.13 kcal·mol
-1
) than to L3 (-1.96 kcal·mol
-1
) as a result of the presence of the more lipophilic 
sulphur in TL3 instead of oxygen in L3.  
 
Figure 9b displays the per-residue contribution for the ∆Eele interaction term. The most important 
residue is Asp97 which contributes almost equally for the two inhibitors (-11.83 kcal·mol
-1 
for L3 and -
11.35 kcal·mol
-1
 for TL3). Differentiation for the ∆Eele term between the two inhibitors is from the 
Tyr80 and Trp84 residues which show the highest discrepancy between the two inhibitors. For L3, the 
∆Eele contributions from the Tyr80 and the Trp84 residues are -3.37 kcal·mol
-1 
and -2.88 kcal·mol
-1
, 
respectively. For TL3, the contributions of these two residues are -1.87 kcal·mol
-1 
and -2.03
 
kcal·mol
-1
, 
respectively. The ∆∆Eele contribution between the two inhibitors from these two residues together is 
2.35 kcal·mol
-1
 which is almost half of the energy contribution of a full H-bond. This emphasizes the 
importance of these two residues for any future development of CviR antagonists.   
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4. CONCLUSIONS 
 
The exact binding modes of a series of recently synthesized and in vitro tested potential QS inhibitors 
were investigated in silico. Consistent with the experimentally measured IC50 values, this molecular 
modeling study using docking scores and energies of binding showed that the lactone based inhibitors 
indeed exhibit stronger binding properties than the thiolactone based class of inhibitors. Molecular 
dynamics simulations of different inhibitor-protein complexes further indicated that the lactone based 
inhibitors were more stable than the thiolactone based ones. Relative to the number of hydrophilic 
residues present in the binding site, the electrostatic effect made a significant contribution to the 
binding for the two series of inhibitors. Certain residues, such as Tyr80 and Trp84, were discriminating 
between the two series of inhibitors with a larger electrostatic contribution for the lactone than the 
thiolactone inhibitors.           
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Table 1: Selected binding energy scores together with the in vitro measured IC50 values for the inhibitors 
under study ranked according to the XP Gscore. 
 
 
 
a
See Ref. [8]. 
 
b 
Pearson correlation coefficient between the in silico calculated docking scores and the in vitro measured IC50 
values. 
 
 
 
 
 Inhibitors IC50 
(µM)
a
 
XP GScore XP 
LipophilicEvdW 
XP 
Electrostatic 
Glide 
Emodel 
Prime MMGBSA 
DG bind 
Prime MMGBSA 
DG bind vdW 
L14   -10.28 -4.90 -1.16 -91.15 -99.19 -49.53 
L15   -10.25 -5.12 -1.19 -96.06 -102.41 -47.95 
L12   -10.02 -4.19 -1.19 -89.99 -100.53 -46.46 
L11   -9.71 -4.66 -1.19 -93.41 -116.59 -51.84 
L4   -9.50 -4.60 -1.20 -94.81 -98.70 -45.54 
L3 0.38 -9.49 -4.63 -1.20 -90.40 -105.54 -46.19 
TL12 0.63 -9.43 -4.14 -1.07 -80.56 -104.45 -44.09 
L9   -9.40 -4.50 -1.18 -96.34 -107.02 -48.73 
L13   -9.40 -4.40 -1.21 -70.66 -101.06 -47.33 
L5   -9.38 -4.64 -1.17 -95.11 -106.60 -48.48 
L8   -9.36 -4.48 -1.17 -92.92 -102.88 -44.60 
TL15 5.00 -9.34 -4.76 -1.09 -89.31 -102.13 -46.57 
L2   -9.34 -4.29 -1.18 -91.56 -94.47 -43.61 
TL14 4.00 -9.32 -4.50 -1.05 -83.97 -101.76 -46.95 
TL1   -9.11 -4.27 -1.18 -89.77 -92.72 -43.31 
TL11 1.40 -9.08 -4.49 -1.09 -86.47 -118.22 -51.14 
L10   -8.76 -4.31 -1.10 -72.97 -99.16 -45.17 
TL3 1.10 -8.61 -4.19 -1.05 -79.07 -104.49 -45.00 
TL4 1.80 -8.60 -4.25 -1.07 -82.58 -101.97 -45.27 
TL2 2.10 -8.58 -3.86 -1.06 -81.62 -100.98 -39.87 
TL5 1.40 -8.53 -4.27 -1.07 -83.29 -102.32 -45.68 
TL8 2.10 -8.51 -3.97 -0.98 -81.19 -115.31 -48.53 
TL9 2.70 -8.36 -4.11 -1.04 -80.41 -109.05 -41.12 
TL13 3.40 -8.20 -3.75 -1.02 -69.40 -95.52 -40.07 
TL1 2.60 -8.18 -3.91 -1.07 -79.01 -96.20 -42.11 
L6   -8.05 -3.92 -1.13 -77.15 -90.41 -42.70 
L7   -7.81 -4.26 -1.09 -74.02 -99.39 -44.11 
L16   -7.78 -4.66 -1.18 -76.10 -101.75 -48.56 
TL10 37.00 -7.67 -3.92 -0.94 -70.76 -97.99 -37.71 
TL6 2.50 -7.29 -4.12 -1.14 -75.55 -112.28 -47.43 
TL7 11.00 -6.95 -4.05 -0.88 -65.21 -98.33 -38.84 
TL16 3.90 -5.69 -3.95 -0.84 -77.05 -109.95 -49.65 
r(Pearson)
b
   0.30 0.25 0.44 0.49 0.34 0.52 
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Table 2: Total and decomposed binding energies of the MD studied complexes (kcal·mol
-1
) together 
with the experimental IC50 values. 
 
 
 
 
 
 
 
a∆Ebinding-gas=  ∆Eele  +∆Evdw
 
   b∆Gbinding =  ∆Eele  +∆Evdw +∆Gsolvation 
 
 
 
 
 
 
Contribution Inhibitor 
 L3 TL3 
∆Eele  -33.54 -28.37 
∆EvdW  -45.31 -46.56 
∆Ebinding-gas
a
 -78.85 -74.93 
∆Gbinding (AMBER-PBSA)
b
 -63.54 -59.11 
∆Gbinding (AMBER-GBSA)
b
 -48.65 -47.60 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
17 
 
 
Figure captions 
 
 
Figure 1: Two dimensional (2D) structures of the lactone (X=O) and thiolactone (X=S) inhibitors 
under study. 
 
Figure 2: Three dimensional (3D) ribbon representation for the CviR monomer. Solid surface in the 
LBD represent the exact binding location of the inhibitors. 
 
Figure 3: 2D ligand interaction diagrams for (a) a potential CviR antagonist (PDB code: 3QP5) and (b) 
a potential CviR agonist (PDB code: 3QP1). 
 
 
Figure 4: 2D and 3D ligand interactions for some selected inhibitors under study in the CviR binding 
site (a) L12, (b)TL12 and (c) L14. 
 
 
Figure 5: RMSD plots for the protein backbone Cα atoms during the 30 ns production simulation for 
(a) dimer complexes and (b) monomer complexes. 
 
 
Figure 6: Per-residue heavy atoms RMSF plots during the 30 ns production simulation for (a) dimer 
complexes and (b) monomer complexes. 
 
Figure 7: Selected H-bonds distances monitored during the 30 ns production simulations for (a, c) 
dimer complexes and (b, d) monomer complexes. 
 
Figure 8: 3D representation for (a) L3 and (b) TL3 with the surrounding amino acid residues. These 
two snapshots were obtained at the end of the 30 ns production simulations. 
 
Figure 9: Per-residue binding energy decompositions calculated using the MMPBSA module of 
AMBER, (a) per-residue contribution to the vdW interaction term and (b) per-residue contribution to 
the electrostatic interaction term. 
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Figure 1: Two dimensional (2D) structures of the lactone (X=O) and thiolactone (X=S) inhibitors 
under study. 
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Figure 2: Three dimensional (3D) ribbon representation for the CviR monomer. Solid surface in the 
LBD represent the exact binding location of the inhibitors.   1 
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Figure 3: 2D ligand interaction diagrams for (a) a potential CviR antagonist (PDB code: 3QP5) and (b) 
a potential CviR agonist (PDB code: 3QP1). 
 
 
(a) 
  
 
 
 
 
 
 
 
  
(b)
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
21 
 
 
Figure 4: 2D and 3D ligand interactions for some selected inhibitors under study in the CviR binding 
site (a) L12, (b)TL12 and (c) L14. 
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Figure 5: RMSD plots for the protein backbone Cα atoms during the 30 ns production simulation for (a) dimer complexes and (b) monomer complexes. 
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Figure 6: Per-residue heavy atoms RMSF plots during the 30 ns production simulation for (a) dimer complexes and (b) monomer complexes. 
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Figure 7: Selected H-bonds distances monitored during the 30 ns production simulations for (a, c) 
dimer complexes and (b, d) monomer complexes. 
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Figure 8: 3D representation for (a) L3 and (b) TL3 with the surrounding amino acid residues. These two snapshots were obtained at the end of the 30 ns production 
simulations. 
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Figure 9: Per-residue binding energy decompositions calculated using the MMPBSA module of 
AMBER, (a) per-residue contribution to the vdW interaction term and (b) per-residue contribution to 
the electrostatic interaction term. 
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